Pharming Group N.V.
PHAR
$16.20
-$0.01-0.06%
NASDAQ
| 06/30/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | 297.20M | 285.75M | 277.56M | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | 297.20M | 285.75M | 277.56M | |
| Cost of Revenue | -- | 35.40M | 30.30M | 31.78M | |
| Gross Profit | -- | 261.80M | 255.44M | 245.78M | |
| SG&A Expenses | -- | 184.43M | 195.14M | 187.17M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -2.18M | 18.71M | 19.18M | |
| Total Operating Expenses | -- | 300.79M | 316.36M | 310.38M | |
| Operating Income | -- | -3.59M | -30.62M | -32.82M | |
| Income Before Tax | -- | -8.49M | -17.20M | -15.41M | |
| Income Tax Expenses | -- | 3.35M | 622.00K | -2.08M | |
| Earnings from Continuing Operations | -- | -11.84 | -17.82 | -13.33 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -11.84M | -17.82M | -13.33M | |
| EBIT | -- | -3.59M | -30.62M | -32.82M | |
| EBITDA | -- | 16.45M | -10.72M | -14.49M | |
| EPS Basic | -- | -0.02 | -0.03 | -0.02 | |
| Normalized Basic EPS | -- | 0.01 | -0.02 | -0.02 | |
| EPS Diluted | -- | -0.02 | -0.03 | -0.02 | |
| Normalized Diluted EPS | -- | 0.01 | -0.02 | -0.02 | |
| Average Basic Shares Outstanding | -- | 2.60B | 2.54B | 2.71B | |
| Average Diluted Shares Outstanding | -- | 2.60B | 2.54B | 2.71B | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |